
Biotechnology
Biotheus Announces Strategic Research Collaboration And Worldwide License Agreement With BioNTech
By PR Newswire

ZHUHAI, China, July 19, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, announced today that it has entered into a strategic research collaboration, option and worldwide license agreement with BioNTech SE ("BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
Under the terms of the agreement, Biotheus will grant BioNTech worldwide, exclusive options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. In addition, Biotheus will grant BioNTech exclusive licenses to existing panels of VHH binders against multiple targets along with options to request Biotheus to generate new panels of VHH binders against targets nominated by BioNTech. In exchange, BioNTech will provide Biotheus with an upfront payment and following option exercise on Biotheus' preclinical-stage bispecific antibody, Biotheus will also be eligible for clinical, regulatory, and commercial milestone payments and tiered single digit royalties.
"Biotheus is deeply committed to leveraging advanced technologies to address unmet medical needs. Partnering with BioNTech, a pioneering leader in novel therapies, significantly furthers our mission. Through this collaboration, we can combine our expertise to discover innovative, potentially transformative therapies for patients worldwide," said Xiaolin Liu, Co-founder, Chairman, and Chief Executive Officer of Biotheus.
About Biotheus
Biotheus Inc. is a clinical-stage biotech company dedicated to the discovery, development, and delivery of novel antibodies and cell therapies to address the unmet medical needs of patients with oncology and inflammatory diseases worldwide. Since its inception, Biotheus has established several innovative platforms for antibody discovery and a proprietary cell therapy that delivers T cell engagers into the tumor microenvironment to eradicate tumor cells. With an experienced development team, Biotheus has built a robust pipeline of ten programs at various stages of clinical development.
For more information about Biotheus, please visit www.biotheus.com.
Contacts:
Biotheus Inc.
Jun Bao
BD@biotheus.com
View original content:https://www.prnewswire.com/news-releases/biotheus-announces-strategic-research-collaboration-and-worldwide-license-agreement-with-biontech-301881622.html
SOURCE Biotheus
First published on Thu, Jul 20, 2023
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
ERPVAR And Equation Technologies Team Up To Support Sage 300 Users Exploring Cloud ERP Options
By PR Newswire
Fulcrum Announces Strategic Vision For Agentic AI To Redefine The Future Of Fieldwork
By PR Newswire
Luware Expands Global Footprint With North American Headquarters In New York
By PR Newswire
Paratus Bolsters Leadership Team With Appointment Of Chief Commercial Officer
By PR Newswire
AARO Joins Forces With Aico & Mercur To Form Unified And Complete Financial Corporate Performance Saas Platform; Michael Teixeira Named Group CEO
By PR Newswire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion